Camp4 Therapeutics

Camp4 Therapeutics

Camp4 Therapeutics launched in 2015 from the labs of Harvard and MIT, where co-founder Richard Young mapped the three-dimensional architecture of gene regulation. CEO Josh Mandel-Brehm, a former Biogen executive, built the company around the insight that regulatory RNA sequences — not the genes themselves — offer the most direct lever for controlling protein output. The founding thesis drew from Young's discovery of super-enhancers, genomic regions that act as master volume knobs for cell-type-specific gene expression. Camp4's core technology decodes these regulatory elements and designs antisense oligonucleotides (ASOs) that upregulate targeted genes, bypassing the delivery challenges that hamstring traditional gene replacement therapies. Camp4 deploys its platform across a pipeline of liver and central nervous system disorders, with a lead candidate in urea cycle disorders — a rare metabolic condition where patients lack the enzyme needed to clear ammonia from the blood. The firm also pursues targets in hepatology and neurodegenerative disease. Rather than delivering a functional gene, Camp4's ASOs amplify the patient's own residual gene expression, a strategy it terms 'regulatory RNA-targeted gene upregulation.' In 2021, the company extended its Series B to $145 million, drawing participation from Enavate Sciences, a Novo Holdings affiliate, alongside existing backers Kaiser Permanente Ventures and Andreessen Horowitz (per the firm, July 2021). The firm maintains research operations in Toronto, built around expertise in nucleic acid chemistry. Camp4 raised $100 million in a Series C crossover round in August 2022, led by Patient Square Capital with participation from existing investors (per the firm, August 2022). The financing signaled preparations for a potential public listing, with a board that has included pharmaceutical-operating veterans from Biogen and Alexion. The company's disclosure of a clinical trial application for its lead program in urea cycle disorders marked a transition from discovery-stage biotech to clinical-stage drug developer. As of early 2025, the firm had not publicly disclosed total headcount, though cross-border operations between Cambridge and Toronto suggest a team capable of managing parallel chemistry and biology workflows. Camp4's architecture differs from syndromic gene-therapy companies by targeting the regulatory layer rather than the coding sequence. Where a conventional gene therapy must deliver a large, functional copy of a gene — often via viral vectors with limited payload capacity — Camp4's ASOs can upregulate the patient's existing gene copy, sidestepping immunogenicity and payload constraints. This regulatory approach also allows titration: the firm can adjust dosing to fine-tune protein levels rather than operating on a binary on/off switch. The company's intellectual proximity to the Young lab at MIT, combined with exclusive licenses to foundational super-enhancer patents, creates a narrow competitive moat in an area where few biotech firms possess both the genomic insights and the therapeutic chemistry to execute on regulatory RNA targets.